ROS1 and non-small cell lung carcinoma: Moreover, preliminary TRIDENT-1 data support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC, with an 86% confirmed objective response rate (ORR) in TKI-naïve ROS1 + NSCLC and 50% in TKI-pretreated patients [13].